| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000021444 |
| Receipt No. | R000024698 |
| Official scientific title of the study | Research for effectiveness and safety of branched stent-graft to aortic arch disease |
| Date of disclosure of the study information | 2016/04/01 |
| Last modified on | 2017/06/14 (Ver. 3) |
| Basic information | ||
| Official scientific title of the study | Research for effectiveness and safety of branched stent-graft to aortic arch disease | |
| Title of the study (Brief title) | Research for effectiveness and safety of branched stent-graft to aortic arch disease | |
| Region |
|
|
| Condition | ||
| Condition | aortic arch disease | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | to evaluate the effectiveness and safety of branched stent graft to aortic arch disease |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | freedom from aortic rupture/enlargement at 6 month postoperatively |
| Key secondary outcomes | |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Single arm |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Uncontrolled |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 1 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Endovascular arotic repair | |
| Interventions/Control_2 | ||
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1) aortic aneurysm located aortic arch to descending aorta and the following one of features are admitted:.
1-a) the largest diameter exceeds 50mm in fusiform aneurysm 1-b) saccular aneurysm containing the risk of rupture 1-c) rapid expansionary more than 5mm/ year 1-d) symptomatic 1-e) risk of rupture or malperfusion 2) the patient who judges the average artificial blood vessel substitution way dies of more than one cardiovascular surgery medicine or, a possibility of the severe complication development is high, and that it's difficult to enforce safely. 3) treatment in aorta stentgraft approved at present doesn't possess more than 20 mm of normal blood vessel in the left common carotid branch part end, and is difficult. I possess an aorta neck of diameter 18 suitable for stentgraft custody-42 mm in a line aorta on the 4). 5) I possess enough blood vessel access for delivery system [biggest outside diameter 26Fr (8.7 mm)] insertion. 6) after a subject had the explanation about the contents of this research, I'm signing agreement sentences. 7) an examinee and the doctor who does this research agree about that a subject goes to a hospital on all follow up days when it's necessary after hand skill operation. |
|||
| Key exclusion criteria | 1)underage (less than 20). 2)a untreated coronary artery disease 3)severe LV dysfunction(LVEF is less than 20%) 4)the patient with pregnancy. 5)the following one of haematological disorder.
(1)Leukocyte decrease (a leukocyte, several 1000 /mm3, less than)(2)Platelet decrease shou (a platelet, several, 50,000 /mm3, less than)(3)Haemorrhagic diathesis or blood clotting abnormality. 6)the morbid overweight patient who can't take a picture of an X-ray picture of an aorta appropriately. 7)chronic obstructive pulmonary disease which requires O Ther outside the hospital daily (COPD) is admitted. 8)it's following hyperesthesia to whether it's both or taboo, and it can't be treated appropriately beforehand.(1)Contrast medium(2)NICHINORU (titanium and nickel alloy), platinum iridium base alloy and polyester(3)Heparin 9)an active whole body infection and/or, patient with infectibility big aneurysm. 10) the past of the cerebrovascular accident (CVA) or a transient brain ischemia attack (TIA) is within 1 month old from a schedule operation day. 11)active enteron bleeding. 12)the patient diagnosed as life expectancy for less than 1 year based on a clear basis (existence of malignant tumor and aging) medically. 13)the patient who participates in a clinical trial of other medical equipment or medical supplies. 14)it seems to refuse blood transfusion. 15)serious recognition shou (As a result, it isn't possible to do the life which became independent outside the Long Term Care Facility to which an agreement explanation note can't be submitted or a hand skill and going to a hospital for follow-up won't be done for a rehabilitation.) 16)the patient who judged a doctor in attendance when it was medical to participate in clinical study psychologically and was difficult. (anatomilcal contraindication) beyond information for use |
|||
| Target sample size | 20 | |||
| Research contact person | |
| Name of lead principal investigator | Hideyuki Shimizu |
| Organization | Keio University School of Medicine |
| Division name | Department of Cardiovascular Surgery |
| Address | 35 Shinanomachi, Shinjuku, Tokyo 160-8582, JAPAN |
| TEL | 03-3353-1211 |
| hideyuki@keio.jp | |
| Public contact | |
| Name of contact person | Akihiro Yoshitake |
| Organization | Keio University School of Medicine |
| Division name | Department of Cardiovascular Surgery |
| Address | 35 Shinanomachi, Shinjuku, Tokyo 160-8582, JAPAN |
| TEL | 03-3353-1211 |
| Homepage URL | |
| akihiro197253@yahoo.co.jp | |
| Sponsor | |
| Institute | Keio University School of Medicine |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Keio University School of Medicine |
| Organization | |
| Division | |
| Category of Funding Organization | Other |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000024698 |